Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Total Current Liabilities (2016 - 2025)

Protalix BioTherapeutics has reported Total Current Liabilities over the past 16 years, most recently at $26.5 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $26.5 million for Q4 2025, up 3.5% from a year ago — trailing twelve months through Dec 2025 was $26.5 million (up 3.5% YoY), and the annual figure for FY2025 was $26.5 million, up 3.5%.
  • Total Current Liabilities for Q4 2025 was $26.5 million at Protalix BioTherapeutics, up from $21.9 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for PLX hit a ceiling of $96.2 million in Q2 2021 and a floor of $21.9 million in Q3 2025.
  • Median Total Current Liabilities over the past 5 years was $32.8 million (2021), compared with a mean of $39.5 million.
  • Biggest five-year swings in Total Current Liabilities: tumbled 67.83% in 2022 and later surged 150.86% in 2024.
  • Protalix BioTherapeutics' Total Current Liabilities stood at $33.2 million in 2021, then dropped by 2.25% to $32.4 million in 2022, then surged by 40.4% to $45.5 million in 2023, then tumbled by 43.73% to $25.6 million in 2024, then grew by 3.5% to $26.5 million in 2025.
  • The last three reported values for Total Current Liabilities were $26.5 million (Q4 2025), $21.9 million (Q3 2025), and $24.1 million (Q2 2025) per Business Quant data.